The START Center for Cancer Research (“START”) is set to have a significant presence at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Known for our commitment to the advancement of cancer research and treatment, we are excited to share that our team of Principal Investigators (PIs) will

New CEO Nick Slack selected to lead the organization in its next phase of growth SAN ANTONIO–(BUSINESS WIRE)–The START Center for Cancer Research, the world’s largest global site network of early phase oncology clinical trials, sets its sights on expanding access to breakthrough research to all communities globally. Currently running

A Marathon and a Sprint The process of developing and bringing new medicines to patients in need is oftentimes lengthy and complex, which is why anything that can be done to expedite this process is critical for patients who are waiting for new treatment options. In the case of B6A,

2023 ASCO – Next Generation Immunotherapy Congratulations to Dr. Emiliano Calvo, Director of START Spain, for leading the discussion of Next Generation Immunotherapy agents on June 4th during the ASCO annual meeting. read Linked Post Here

2022 ESMO IMMUNO-ONCOLOGY (ESMO IO) ACTIVITY SUMMARY The START Center investigators contributed as authors to posters and abstracts at this year’s ESMO IO meeting in Geneva, Switzerland. Congratulations to the START physician team, Dr. Kyriakos Papadopoulos, Dr. Nehal Lakhani, Dr. Manish Sharma, Dr. Amita Patnaik, Dr. Drew Rasco, and Dr.

Download Announcement ALAMEDA, Calif.–(BUSINESS WIRE)–Dec. 8, 2022– Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclindependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors. The